Concert Secures Celgene As Its Latest Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Concert Pharmaceuticals has garnered a third partnership for its deuterium-modification platform as the Massachusetts biotech continues to push its internal pipeline forward on its own.